Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Jan Philipp, Bewersdorf"'
Autor:
Abdulrahman Alhajahjeh, Lara K. Rotter, Jessica M. Stempel, Alyssa A. Grimshaw, Jan Philipp Bewersdorf, Ondrej Blaha, Tariq Kewan, Nikolai A. Podoltsev, Rory M. Shallis, Lourdes Mendez, Maximilian Stahl, Amer M. Zeidan
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEMost clinical trials are conducted exclusively in high-income countries (HICs), with only a small fraction involving centers from low-middle income countries (LMICs). However, studies evaluating the global distribution of clinical trials in le
Externí odkaz:
https://doaj.org/article/7cf99fbf35d340edaf0a2d0f11b7b88d
Autor:
Amer M. Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Background: TP53 mutations are associated with an adverse prognosis in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). However, the integrated genetic, epigenetic, and immunologic landscape of TP53 -mutated AML/HR-MDS
Externí odkaz:
https://doaj.org/article/607d9f5536614146a1ff9b6d9aed6dd7
Autor:
Fabio Efficace, Rena Buckstein, Gregory A. Abel, Johannes M. Giesinger, Pierre Fenaux, Jan Philipp Bewersdorf, Andrew M. Brunner, Rafael Bejar, Uma Borate, Amy E. DeZern, Peter Greenberg, Gail J. Roboz, Michael R. Savona, Francesco Sparano, Jacqueline Boultwood, Rami Komrokji, David A. Sallman, Zhuoer Xie, Guillermo Sanz, Hetty E. Carraway, Justin Taylor, Stephen D. Nimer, Matteo Giovanni Della Porta, Valeria Santini, Maximilian Stahl, Uwe Platzbecker, Mikkael A. Sekeres, Amer M. Zeidan
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promis
Externí odkaz:
https://doaj.org/article/cf17fd5c0de047b1a6c103df622ef528
Autor:
Nina C. Teske, Susanne Dyckhoff-Shen, Paul Beckenbauer, Jan Philipp Bewersdorf, Joo-Yeon Engelen-Lee, Sven Hammerschmidt, Roland E. Kälin, Hans-Walter Pfister, Matthijs C. Brouwer, Matthias Klein, Rainer Glass, Diederik van de Beek, Uwe Koedel
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-16 (2023)
Abstract Background Brain pericytes participate in the regulation of cerebral blood flow and the maintenance of blood–brain barrier integrity. Because of their perivascular localization, their receptor repertoire, and their potential ability to res
Externí odkaz:
https://doaj.org/article/e4f425e238dc4252905d4a9ece08674f
Publikováno v:
Hemato, Vol 2, Iss 4, Pp 748-763 (2021)
About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a TP53 mutation (mTP53-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median ov
Externí odkaz:
https://doaj.org/article/ddf4851459fe42ddaaaa42e339d9b80e
Publikováno v:
The Cancer Journal. 29:195-202
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff6cbd6f9a2b3434268051e04a75bd8e
https://doi.org/10.1097/ppo.0000000000000658
https://doi.org/10.1097/ppo.0000000000000658
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:522-528
Acute myeloid leukemia (AML) is the most common acute leukemia in adults in the United States and has seen the approval of several novel agents over the past decade. Similar to treatments for other hematologic and solid malignancies, these novel agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14b1e0f4535842bd77652586d2caa484
https://doi.org/10.6004/jnccn.2023.70012
https://doi.org/10.6004/jnccn.2023.70012
Publikováno v:
The Cancer Journal. 29:203-211
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::037208017d125764bc667c5f62f35282
https://doi.org/10.1097/ppo.0000000000000666
https://doi.org/10.1097/ppo.0000000000000666
Autor:
Melinda Wang, Frank Ulrich Weiss, Xiaojia Guo, Thomas Kolodecik, Jan Philipp Bewersdorf, Loren Laine, Markus M. Lerch, Gary Desir, Fred S. Gorelick
Publikováno v:
Pancreatology. 23:158-162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4363b1ccb3ecdc124b8a2456652ffb08
https://doi.org/10.1016/j.pan.2023.01.001
https://doi.org/10.1016/j.pan.2023.01.001
Publikováno v:
Therapeutic Advances in Hematology, Vol 11 (2020)
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML).
Externí odkaz:
https://doaj.org/article/f87c91fe55ed42df8f784ced8638bc24